Skip to main content
    L

    Lineage Cell Therapeutics Inc (LCTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.80
    -0.11 (-12.45%)

    Market Cap: $231.35M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Lineage Cell Therapeutics Inc (LCTX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Lineage Cell Therapeutics (LCTX) trades at 18.7x sales and 3.0x book value. Its P/S of 18.7x is below its 5-year median of 20.5x. Its forward P/E is 30.7x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E30.7x
    Price to sales18.7x
    Price to book3.0x
    PEGN/A
    FCF yield-13.1%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 18.7% below 23.0x and its P/B is 11.1% above 2.7x.

    MultipleCurrent5-year median10-year median
    P/S18.7x20.5x23.0x
    P/B3.0x3.1x2.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 114 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 0.7x in 2020 to 72.6x in 2017.

    Year endPriceP/EP/SP/B
    2025$1.67N/A26.3x8.6x
    2024$0.50N/A10.1x1.3x
    2023$1.09N/A20.9x3.0x
    2022$1.17N/A13.5x2.7x
    2021$2.45N/A1.0x4.5x
    2020$1.76N/A0.7x2.7x
    2019$0.89N/A36.7x1.2x
    2018$0.91N/A23.2x1.2x
    2017$2.15N/A72.6x1.7x
    2016$3.6111.3x58.6x3.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About LCTX

    What is LCTX's forward P/E ratio?

    Lineage Cell Therapeutics has a forward P/E ratio of 30.7x.

    Is LCTX stock overvalued?

    GNG's valuation label for LCTX is Fairly valued.

    What is LCTX's price to sales ratio?

    Lineage Cell Therapeutics has a price to sales ratio of 18.7x.